Literature DB >> 10027329

Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer.

A Hügel1, N Wernert.   

Abstract

The aim of the present study was to find out whether increasing malignancy of prostate carcinoma correlates with an overall increase of loss of heterozygosity (LOH), and whether LOH typing of microdissected tumour areas can help to distinguish between multifocal or clonal tumour development. In 47 carcinomas analysed at 25 chromosomal loci, the overall LOH rate was found to be significantly lower in grade 1 areas (2.2%) compared with grade 2 (9.4%) and grade 3 areas (8.3%, P = 0.007). A similar tendency was found for the mean fractional allele loss (FAL, 0.043 for grade 1, 0.2 for grade 2 and 0.23 for grade 3, P = 0.0004). Of 20 tumours (65%) with LOH in several microdissected areas, 13 had identical losses at 1-4 loci within two or three areas, suggesting clonal development of these areas. Markers near RB, DCC, BBC1, TP53 and at D13S325 (13q21-22) showed higher loss rates in grades 2 and 3 (between 25% and 44.4%) compared with grade 1 (0-6.6%). Tumour-suppressor genes (TSGs) near these loci might, thus, be important for tumour progression. TP53 mutations were detected in 27%, but BBC1 mutations in only 7%, of samples with LOH. Evaluation of all 25 loci in every tumour made evident that each prostate cancer has its own pattern of allelic losses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027329      PMCID: PMC2362403          DOI: 10.1038/sj.bjc.6690087

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  A device for processing large acrylamide gels.

Authors:  B Bender; O D Wiestler; A von Deimling
Journal:  Biotechniques       Date:  1994-02       Impact factor: 1.993

2.  Infrequent RAS oncogene mutations in human prostate cancer.

Authors:  J W Moul; P A Friedrichs; R S Lance; S M Theune; E H Chang
Journal:  Prostate       Date:  1992       Impact factor: 4.104

3.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.

Authors:  R Sadasivan; R Morgan; S Jennings; M Austenfeld; P Van Veldhuizen; R Stephens; M Noble
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

Review 4.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.

Authors:  E J Kuhn; R A Kurnot; I A Sesterhenn; E H Chang; J W Moul
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

Review 5.  Tumor suppressor genes in prostatic oncogenesis.

Authors:  R Bookstein
Journal:  J Cell Biochem Suppl       Date:  1994

6.  Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1.

Authors:  J C Zenklusen; J C Thompson; P Troncoso; J Kagan; C J Conti
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

7.  A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas.

Authors:  A von Deimling; B Bender; D N Louis; O D Wiestler
Journal:  Neuropathol Appl Neurobiol       Date:  1993-12       Impact factor: 8.090

8.  Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer.

Authors:  J Trapman; H F Sleddens; M M van der Weiden; W N Dinjens; J J Konig; F H Schroder; P W Faber; F T Bosman
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

9.  Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas.

Authors:  X Gao; K V Honn; D Grignon; W Sakr; Y Q Chen
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

10.  Activated ras alleles in human carcinoma of the prostate are rare.

Authors:  P H Gumerlock; U R Poonamallee; F J Meyers; R W deVere White
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

View more
  9 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Genes and proteins differentially expressed during in vitro malignant transformation of bovine pancreatic duct cells.

Authors:  R Jesnowski; Dmitri Zubakov; Ralf Faissner; Jörg Ringel; Jörg D Hoheisel; Ralf Lösel; Martina Schnölzer; Matthias Löhr
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 3.  [Laser microdissection in the molecular oncology of prostate cancer].

Authors:  N Wernert
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

4.  [Prostate cancer research. Biomarkers as promising options for optimized diagnosis and treatment].

Authors:  J Ellinger; A von Rücker; N Wernert; R Büttner; P J Bastian; S C Müller
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 5.  Clonal origin and spread of metastatic prostate cancer.

Authors:  Jamie L Van Etten; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2016-03-21       Impact factor: 5.678

Review 6.  Tumor focality in prostate cancer: implications for focal therapy.

Authors:  Markos Karavitakis; Hashim U Ahmed; Paul D Abel; Steven Hazell; Mathias H Winkler
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

7.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

8.  Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.

Authors:  R Thuret; K Chantrel-Groussard; A-R Azzouzi; J-M Villette; S Guimard; P Teillac; P Berthon; A Houlgatte; A Latil; O Cussenot
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

9.  Epigenetics in prostate cancer treatment.

Authors:  Katelyn Jones; Yanquan Zhang; Yifan Kong; Elia Farah; Ruixin Wang; Chaohao Li; Xinyi Wang; ZhuangZhuang Zhang; Jianlin Wang; Fengyi Mao; Xiaoqi Liu; Jinghui Liu
Journal:  J Transl Genet Genom       Date:  2021-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.